Safety, virology, pharmacokinetics, and clinical experience of high-dose intravenous sotrovimab for the treatment of mild to moderate COVID-19: an open-label clinical …
…, S Parra, E Juarez, R Hernandez-Loy… - Open Forum …, 2023 - academic.oup.com
Background Five hundred milligrams of intravenous (IV) sotrovimab has been shown to be
well tolerated and efficacious against pre-Omicron strains in treating patients with mild to …
well tolerated and efficacious against pre-Omicron strains in treating patients with mild to …